Condition
Dengue Disease
Total Trials
4
Recruiting
1
Active
1
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
67%
2 of 3 completed with results
Key Signals
2 with results100% success
Data Visualizations
Phase Distribution
3Total
P 1 (1)
P 2 (2)
Trial Status
Completed3
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT07409857RecruitingPrimary
International Registry of Dengue Infection in Congenital Bleeding Disorders (DengueCBDR)
NCT05507450Phase 2CompletedPrimary
Safety and Immunogenicity of Three V181 Dengue Vaccine Potencies in Adults (V181-003)
NCT00875524Phase 2Completed
Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects
NCT01502358Phase 1CompletedPrimary
Evaluation of the Safety and the Ability of a DNA Vaccine to Protect Against Dengue Disease
Showing all 4 trials